NovoCure Ltd. (NASDAQ:NVCR)’s share price traded down 7.6% during trading on Tuesday . The stock traded as low as $11.26 and last traded at $11.27, with a volume of 155,793 shares changing hands. The stock had previously closed at $12.20.

Several equities analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of NovoCure in a research report on Wednesday. Zacks Investment Research cut NovoCure from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $28.57.

The company has a 50 day moving average of $11.39 and a 200 day moving average of $14.06. The stock’s market capitalization is $939.01 million.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Monday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.09. The business earned $13.10 million during the quarter, compared to the consensus estimate of $23.65 million. On average, equities research analysts forecast that NovoCure Ltd. will post ($1.38) EPS for the current fiscal year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares in the company, valued at $3,966,788.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of hedge funds recently bought and sold shares of the company. Hartline Investment Corp bought a new stake in NovoCure during the fourth quarter worth $1,143,000. Morgan Stanley bought a new stake in NovoCure during the fourth quarter worth $9,619,000. Finally, Century Capital Management LLC bought a new stake in NovoCure during the fourth quarter worth $2,970,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.